A U.S. Court of Appeals panel upheld a lower-court ruling blocking compounders’ challenges to the FDA’s removal of Eli Lilly and Novo Nordisk GLP-1 drugs from the agency’s shortage list. The court effectively sidestepped whether FDA removal requires a notice-and-comment rulemaking after determining the shortage has ended. The decision maintains the FDA’s ability to update shortage status without extended procedural steps, a practical issue for manufacturing entities relying on shortage designations and for patients affected by supply constraints. For biopharma stakeholders, the ruling narrows the legal path for parties arguing that FDA shortage-list changes demand full rulemaking, keeping the current regulatory mechanics intact.